Evolocumab superior to ezetimibe in lowering LDL cholesterol

March 31, 2014

Evolocumab, an injected form of a class of drugs called PCSK9 inhibitors that lower low-density lipoprotein cholesterol, also known as LDL-C or "bad cholesterol," outperformed ezetimibe with few side effects in patients unable to take statins, according to research from GAUSS-2 presented at the American College of Cardiology's 63rd Annual Scientific Session.

High LDL cholesterol is considered a major risk factor for cardiovascular disease. Statins are commonly prescribed to reduce that risk. Currently is one of the few options to lower LDL-C for patients who cannot tolerate statins, but it is less effective than statins in decreasing LDL-C.

GAUSS-2 is a 14-country, 12-week double-blind comparison of subcutaneously administered evolocumab versus oral ezetimibe in patients with high cholesterol who were unable to tolerate effective doses of at least two different statins. In this phase III study, half of patients tried three statins unsuccessfully, and 22 percent couldn't tolerate any of at least four different . The patients had a minimum LDL-C level of 193 mg/dL.

A total of 307 patients were randomly assigned to one of two evolocumab regimens (140 mg every two weeks or 420 mg per month, plus daily placebo) or one of two ezetimibe groups (a placebo injection every two weeks or monthly, plus 10 mg oral ezetimibe daily). Mean age was 62 years, and 46 percent of patients were women.

The primary endpoints of LDL-C reductions from baseline were met: 53 percent to 56 percent decrease of LDL-C from baseline at week 12 in evolocumab-treated patients, corresponding to a 37 percent to 39 percent LDL-C decrease with ezetimibe. Musculoskeletal were reported in 12 percent of patients on evolocumab compared to 23 percent on ezetimibe. More than 94 percent of all enrolled patients completed the study. The study drug was stopped because of treatment-related side effects in 8 percent of evolocumab patients and 13 percent of ezetimibe patients. Safety data for evolcumab versus ezetimibe include the following side effects: headache (8 percent vs. 9 percent), muscle pain (8 percent vs. 18 percent), pain in extremities (7 percent vs. 1 percent), muscle spasms (6 percent vs. 4 percent), fatigue (4 percent vs. 10 percent), nausea (4 percent vs. 7 percent), diarrhea (2 percent vs. 7 percent), sensation of tingling, prickling or burning known as paresthesia (1 percent vs. 5 percent). Patients who were taking low-dose statins were more likely to develop muscle pain in both study arms than those who took no statins (evolocumab, 17 percent vs. 6 percent; ezetimibe, 21 percent vs. 17 percent).

"We have a growing population of patients treated with at least two different types of statins who still experience side effects so much they want to discontinue the drug," said Erik S.G. Stroes, M.D., chair and professor at the Department of Vascular Medicine in Amsterdam's Medical Center and the study's principal investigator. "The one big difference between our study and others in patients at increased cardiovascular risk is that for these patients, we don't have a good alternative treatment – no drug with robust LDL-lowering potency and good tolerability. For clinicians trained to solve problems, an unmet clinical need is a big issue."

Earlier studies indicate that more than 75 percent of patients who failed one statin can still do well on a second statin drug. This finding makes patients who have been unable to tolerate two or more statins a particularly challenging group.

Stroes noted that clinicians have debated whether cardiovascular patients would accept a drug administered by injection, but the study's cardiovascular physicians and internists found few problems with the subcutaneous regimen. Evolocumab must be delivered by this route because it's a fully human monoclonal antibody, a protein that will be broken down in the stomach and bowel if taken orally.

"What's innovative here is that if you give a drug, it's hardly ever specific; statins, for example, can work on a lot of organs," Stroes said. "An antibody is, in and of itself, inert. It binds selectively to a particular sequence on a protein or bacteria and can have a predictable effect on a particular system. That's most likely why evolocumab has a good safety profile with very high efficacy. This study suggests that statin-induced myopathy [muscle discomfort] may be due to another molecular pathway and is not related to LDL-C lowering per se."

There is no generally accepted definition of statin intolerance yet, Stroes said. The GAUSS-3 study, planned to start in the second half of 2014, will include a separate placebo-controlled re-exposure to statin before evolocumab therapy.

"It will help in further delineating statin intolerance and how that should be defined in clinical practice," he said.

Stroes noted two limitations to the study. Reducing LDL-C levels has been demonstrated to translate into a reduced risk of cardiovascular events primarily with treatment. The benefit of evolocumab on cardiovascular endpoints awaits the results of the ongoing FOURIER trial. Additionally, the 12-week duration of this study was rather short considering that the majority of require life-long treatment to manage LDL-C. The good tolerability observed in this study also needs confirmation in the ongoing long-term trials, Stroes said.

Explore further: Evolocumab safely drops LDL cholesterol well below statin-only baseline

More information: This study will be simultaneously published online in the Journal of the American College of Cardiology at the time of presentation.

Related Stories

Evolocumab safely drops LDL cholesterol well below statin-only baseline

March 31, 2014
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 ...

Alternative treatment for cholesterol shows promise

March 30, 2014
An experimental treatment has shown promise in lowering bad cholesterol, offering hope for people at risk of heart disease but who cannot tolerate drugs known as statins, researchers said Sunday.

Significantly improved chance of heart attack survival with high-potency statin treatment

February 20, 2014
(Medical Xpress)—A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking ...

Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins

March 11, 2013
Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt ...

Low-dose statins good option for some heart patients, study finds

February 10, 2014
(HealthDay)—A new analysis suggests that people at high risk for heart disease who can't take high-dose statin drugs to lower their cholesterol might benefit from a treatment combination that includes taking a low-dose ...

New drug significantly lowers bad cholesterol

November 6, 2012
For many people with high cholesterol, statins serve as the first line of treatment. However, some patients are unable to effectively reduce their low-density lipoprotein cholesterol (LDL cholesterol) or "bad cholesterol" ...

Recommended for you

New discovery could reverse tissue damage caused by heart attacks

July 25, 2017
A new discovery by University of Bristol scientists helps to explain how cells which surround blood vessels, called pericytes, stimulate new blood vessels to grow with the hormone 'leptin' playing a key role. Leptin is produced ...

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.